ClinicalTrials.gg
TerminatedNCT01616758Updated Mar 8, 2024Results posted

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

A Phase 2 interventional study of GTx-024 9mg in Metastatic Breast Cancer, sponsored by GTx. Terminated at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by GTx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification. Key secondary endpoints of objective response rate, progression free survival, time to progression, duration of response, effects on physical function, and effects on tumor progression in women with Androgen Receptor positive breast cancer will also be assessed.

Read the detailed description

This is an open label, multicenter study to assess the safety and efficacy of GTx-024 in female subjects who have estrogen receptor (ER) positive metastatic breast cancer and who have responded previously to hormone therapy. Subjects may have received up to 3 prior hormonal therapies for the treatment of breast cancer. Subjects must have responded to adjuvant hormonal therapy for > 3 years or hormonal therapy for metastatic disease for > 6 months before progression to be eligible for this study.

The primary efficacy analysis will be the clinical benefit in subjects with AR positive breast cancer at 6 months as measured by a modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) classification. Key secondary endpoints of clinical benefit in all subjects and AR negative subjects, as well as objective response rate, progression free survival, time to progression, duration of response, incidence of SREs, and time to first SRE in subsets based on AR status will also be assessed.

02

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

This study's enrollment of 22 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Give voluntary, signed in accordance with institutional policies.
  2. Be a woman that has been diagnosed with ER positive breast cancer.
  3. Have metastatic breast cancer with prior to enrollment or bone only disease prior to enrollment. A measurable lesion is defined as one lesion whose longest diameter (LD) can be accurately measured as 10 mm CT or MRI technique by using a 5 mm contiguous reconstruction algorithm. Measurable lesions must be at least 2 times the slice thickness or at least two times the size of the CT scan interval cut. Patients with bone only disease and non-measurable lesions are eligible.
  4. Be clinically confirmed as . Subjects must have undergone the onset of spontaneous, medical or surgical menopause prior to the start of this study.(Spontaneous menopause is defined as the natural cessation of ovarian function as indicated by being amenorrheic for at least 12 months. If the subject has been amenorrheic for > or equal to 6 months but \< 12 months, they must have a serum FSH concentration of > or equal to 50 mIU/mL and an estradiol concentration of less than or equal to 25 pg/mL. Medical menopause is defined as treatment with a luteinizing hormone receptor hormone agonist and surgical menopause is defined as bilateral oophorectomy).
  5. Have been treated and responded to previous hormonal therapy for 3 years or previous hormonal therapy for metastatic disease for 6 months prior to disease progression.
  6. Have not had radiation therapy for breast cancer within 2 weeks of randomization in this study and are not planned to have radiation therapy during participation in this study.
  7. Be willing to provide a formalin-fixed, paraffin-embedded block(s) of cancerous tissue from a of a metastatic tumor lesion(s) collected during the two (2) years prior to study entry or as a component of enrollment in the study for determination of AR and ER status. Tissue samples from a biopsy of a primary tumor lesion will also be provided if available.
  8. Serum creatinine 2.0 mg/dL
  9. Have score 2.
  10. Be age 18 years.

Exclusion criteria

Exclusion Criteria:

  1. Have triple negative breast cancer
  2. Have, in the judgment of the Investigator, a concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol
  3. Have uncontrolled hypertension (systolic blood pressure greater than 150 mm Hg and/or diastolic blood pressure greater than 100 mm Hg despite treatment with antihypertensive drugs)
  4. Untreated congestive heart failure or untreated angina
  5. Have Stage 4 (COPD)
  6. Have positive screen for consisting of HBsAg (Hepatitis B Surface Antigen), unless subject was diagnosed > 10 years prior to enrollment and no evidence of active liver disease
  7. The presence of consistently abnormal clinical laboratory test (Appendix B) values which are considered clinically significant. In addition, any subject with total above 2 times the (ULN) or liver enzymes ( /SGOT or AST/SGPT) above 1.5 times the ULN without evidence of liver or above 5 times the ULN in subjects with evidence of liver metastases will not be admitted to the study
  8. Have positive screen for hepatitis A antibody IgM or
  9. Have received chemotherapy for metastatic breast cancer within the 3 months prior to enrollment in the study or be expected to receive chemotherapy for metastatic breast cancer during the study
  10. Be currently taking testosterone, methyltestosterone, oxandrolone (Oxandrin®),oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone (DHEA), androstenedione, and other androgenic compounds, including herbals), or antiandrogens. Previous therapy with testosterone and testosterone-like agents is acceptable with a 30-day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the medical monitor (1-877-693-2723) for this study to determine appropriate ).
  11. Have untreated or uncontrolled
  12. Have been diagnosed with or treated for cancer within the previous two years, other than breast cancer or non-melanoma carcinoma of the skin.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    GTx-024 9mg

    GTx-024 dosage of three soft gels once daily to equal 9mg

    Drug: GTx-024 9mg

Interventions

  • Also known as: GTx-024 dosage of three soft gels once daily to equal 9mg

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast Cancer

    N=17 of 22 subjects with AR Positive Breast Cancer - Clinical Benefit is defined as a complete response (CR), partial response (PR), or stable disease (SD).

    Time frame: 6 months

Secondary outcomes

  1. Percentage of Subjects Treated With GTx024 With Clinical Benefit (All Subjects)

    Clinical Benefit is defined as a complete response (CR), partial response (PR), or stable disease (SD).

    Time frame: 6 Months

  2. Percentage of Subjects Treated With GTx024 Achieving Objective Response by 1 Year of Treatment

    Objective Response is defined as achieving Complete or Partial Response on Tumor Assessments Note: Due to zero subject achieving response, all subsequent outcome measures related to response cannot be conducted.

    Time frame: 1 Year

07

Results

Posted Mar 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneGTx-024 9mg
Started22
Evaluable20
Completed0
Not completed22
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Disease progression18
Withdrew: Study termination by sponsor1

Outcome measures

PrimaryPercentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast Cancer

N=17 of 22 subjects with AR Positive Breast Cancer - Clinical Benefit is defined as a complete response (CR), partial response (PR), or stable disease (SD).

Time frame:
6 months
Reported as:
Count of participants · Participants
Percentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast Cancer
ParticipantsGTx-024 9mg
Percentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast Cancer6
SecondaryPercentage of Subjects Treated With GTx024 With Clinical Benefit (All Subjects)

Clinical Benefit is defined as a complete response (CR), partial response (PR), or stable disease (SD).

Time frame:
6 Months
Reported as:
Count of participants · Participants
Percentage of Subjects Treated With GTx024 With Clinical Benefit (All Subjects)
ParticipantsGTx-024 9mg
Percentage of Subjects Treated With GTx024 With Clinical Benefit (All Subjects)7
SecondaryPercentage of Subjects Treated With GTx024 Achieving Objective Response by 1 Year of Treatment

Objective Response is defined as achieving Complete or Partial Response on Tumor Assessments Note: Due to zero subject achieving response, all subsequent outcome measures related to response cannot be conducted.

Time frame:
1 Year
Reported as:
Count of participants · Participants
Percentage of Subjects Treated With GTx024 Achieving Objective Response by 1 Year of Treatment
ParticipantsGTx-024 9mg
Percentage of Subjects Treated With GTx024 Achieving Objective Response by 1 Year of Treatment0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GTx-024 9mg0/22 (0%)2/22 (9.1%)22/22 (100%)
Most frequent serious events
Most frequent serious events
EventGTx-024 9mg
Pathologic Hip FractureMusculoskeletal and connective tissue disorders1/22
Bone pain of ChestMusculoskeletal and connective tissue disorders1/22
Most frequent other events
Most frequent other events
EventGTx-024 9mg
NauseaGastrointestinal disorders8/22
FatigueGeneral disorders8/22
ArthralgiaMusculoskeletal and connective tissue disorders6/22
Back painMusculoskeletal and connective tissue disorders6/22
Hot FlushVascular disorders6/22
DiarrhoeaGastrointestinal disorders4/22
HeadacheNervous system disorders4/22
Muscle SpasmsMusculoskeletal and connective tissue disorders3/22

Baseline characteristics

All Enrolled patients Note: 20 patients were deemed as evaluable

Age, Customized
Age, Customized(Participants)GTx-024 9mg
≥18 years22
Sex/Gender, Customized
Sex/Gender, Customized(Participants)GTx-024 9mg
Female22
08

Study locations

4 sites
  • AMPM Research Clinic
    Miami, Florida 33145, United States
  • Illinois Cancer Care, PC
    Peoria, Illinois 61615, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02110, United States
  • Commonwealth Hematology-Oncology
    Lawrence, Massachusetts 01841, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2013 to primary completion in Jun 2014, 14 months.

Results were first posted in Mar 2024, 9 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2012
First posted
Jun 12, 2012
StartActual
Apr 2013
Primary completionActual
Jun 2014
CompletionActual
Mar 2016
Results first posted
Mar 8, 2024
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01616758
Lead sponsor
GTx
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
Apr 2013
Primary completion
Jun 2014
Completion
Mar 2016
Results posted
Mar 8, 2024
Last update
Mar 8, 2024

Study contacts

Mayzie Johnston, PharmD
study director · GTx

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ostarine

Start the discussion